Antiandrogen Effects of Mifepristone on Coactivator and Corepressor Interactions with the Androgen Receptor

Molecular Endocrinology

Volumn 18, Issue 1, 2004, Pages 70-85

  Song, Liang Nian ^a   Coghlan, Meghan ^a   Gelmann, Edward P ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BETA CATENIN; BICALUTAMIDE; CELL NUCLEUS RECEPTOR; CYPROTERONE ACETATE; HYBRID PROTEIN; HYDROXYFLUTAMIDE; METRIBOLONE; MIFEPRISTONE; PROSTATE SPECIFIC ANTIGEN; RETINOID; THYROID HORMONE RECEPTOR; TRANSCRIPTION FACTOR AP 2; VIRUS PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; GENE MUTATION; HERPES SIMPLEX VIRUS; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MALE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INTERACTION; REPORTER GENE; TWO HYBRID SYSTEM; WILD TYPE;

ANDROGEN ANTAGONISTS; ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; GENES, REPORTER; LUCIFERASES; MIFEPRISTONE; MUTAGENESIS, SITE-DIRECTED; RECEPTORS, ANDROGEN; RECOMBINANT PROTEINS; REPRESSOR PROTEINS;

ANIMALIA; HERPES; MAMMARY TUMOR ONCOVIRUS; MAMMARY TUMOR VIRUS; MOUSE MAMMARY TUMOR VIRUS; MURINAE; MURINE MAMMARY TUMOR VIRUS; ONCOVIRINAE; SIMPLEXVIRUS; TUMOR VIRUS;

EID: 0346025352     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2003-0189     Document Type: Article

References (58)

1. He B, Kemppainen JA, Wilson EM 2000 FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 275:22986-22994
2. Onate SA, Tsai SY, Tsai MJ, O'Malley BW 1995 Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270: 1354-1357
3. Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H 1996 TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 15:3667-3675
4. Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR 1996 GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc Natl Acad Sci USA 93:4948-4952
5. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, Otto N, Joschko S, Scholz P, Wegg A, Basler S, Schafer M, Egner U, Carrondo MA 2000 Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 275:26164-26171
6. Sack JS, Kish KF, Wang C, Attar RM, Kiefer SE, An Y, Wu GY, Scheffler JE, Salvati ME, Krystek Jr SR, Weinmann R, Einspahr HM 2001 Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci USA 98:4904-4909
7. Matias PM, Carrondo MA, Coelho R, Thomaz M, Zhao XY, Wegg A, Crusius K, Egner U, Donner P 2002 Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45:1439-1446
8. Smith CL, Nawaz Z, O'Malley BW 1997 Coactivator and compressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11:657-666
9. Zhang X, Jeyakumar M, Petukhov S, Bagchi MK 1998 A nuclear receptor compressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol Endocrinol 12:513-524
10. Schulz M, Eggert M, Baniahmad A, Dostert A, Heinzel T, Renkawitz R 2002 RU486-induced glucocorticoid receptor agonism is controlled by the receptor N terminus and by corepressor binding. J Biol Chem 277:26238-26243
11. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB 1997 The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 11:693-705
12. Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP 1998 The nuclear compressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol 18:1369-1378
13. Dotzlaw H, Moehren U, Mink S, Cato AC, Iniguez Lluhi JA, Baniahmad A 2002 The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol 16:661-673
14. Liao G, Chen LY, Zhang A, Godavarthy A, Xia F, Ghosh JC, Li H, Chen JD 2003 Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem 278:5052-5061
15. Sadi MV, Walsh PC, Barrack ER 1991 Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 67:3057-3064
16. Trachtenberg J, Walsh PC 1982 Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J Urol 127:466-471
17. Gonor SE, Lakey WH, McBlain WA 1984 Relationship between concentrations of extractable and matrix-bound nuclear androgen receptor and clinical response to endocrine therapy for prostatic adenocarcinoma. J Urol 131:1196-1201
18. Benson Jr RC, Gorman PA, O'Brien PC, Holicky EL, Veneziale CM 1987 Relationship between androgen receptor binding activity in human prostate cancer and clinical response to endocrine therapy. Cancer 59: 1599-1606
19. Rennie PS, Bruchovsky N, Goldenberg SL 1988 Relationship of androgen receptors to the growth and regression of the prostate. Am J Clin Oncol 11 :S13-S17
20. Castellanos JM, Galan A, Calvo MA, Schwartz S 1982 Predicting response of prostatic carcinoma to endocrine therapy. Lancet 1:448
21. Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T 2000 Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 164:1992-1995
22. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ 1999 Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 Study. J Clin Oncol 17:2506
23. Spitz IM, Bardin CW 1993 Mifepristone (RU 486) - a modulator of progestin and glucocorticoid action. N Engl J Med 329:404-412
24. Rocereto TF, Saul HM, Aikins Jr JA, Paulson J 2000 Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol Oncol 77:429-432
25. Romieu G, Maudelonde T, Ulmann A, Pujol H, Grenier J, Cavalie G, Khalaf S, Rochefort H 1987 The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer 74:455-461
26. Perrault D, Eisenhauer EA, Pritchard KI, Panasci L, Norris B, Vandenberg T, Fisher B 1996 Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 14:2709-2712
27. Eid MA, Lewis RW, Kumar MV 2002 Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL). Mol Cancer Ther 1:831-840
28. El Etreby MF, Liang Y, Lewis RW 2000 Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture. Prostate 43:31-42
29. El Etreby MF, Liang Y, Johnson MH, Lewis RW 2000 Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice. Prostate 42:99-106
30. Lin MF, Kawachi MH, Stallcup MR, Grunberg SM, Lin FF 1995 Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone. Prostate 26:194-204
31. Kemppainen JA, Lane MV, Sar M, Wilson EM 1992 Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem 267:968-974
32. Kuil CW, Berrevoets CA, Mulder E 1995 Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action. J Biol Chem 270:27569-27576
33. Wong CI, Zhou ZX, Sar M, Wilson EM 1993 Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains. J Biol Chem 268:19004-19012
34. Kuil CW, Mulder E 1996 Deoxyribonucleic acid-binding ability of androgen receptors in whole cells: implications for the actions of androgens and antiandrogens. Endocrinology 137:1870-1877
35. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, DeVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS 1997 Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11:450-459
36. Wilding G, Chen M, Gelmann EP 1989 Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14:103-115
37. Berrevoets CA, Veldscholte J, Mulder E 1993 Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors. J Steroid Biochem Mol Biol 46:731-736
38. Shang Y, Myers M, Brown M 2002 Formation of the androgen receptor transcription complex. Mol Cell 9:601-610
39. Song LN, Herrell R, Byers S, Shah S, Wilson EM, Gelmann EP 2003 β-Catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol 23:1674-1687
40. He B, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson EM 1999 Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem 274:37219-37225
41. Berrevoets CA, Doesburg P, Steketee K, Trapman J, Brinkmann AO 1998 Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor 2). Mol Endocrinol 12:1172-1183
42. Pang S, Dannull J, Kaboo R, Xie Y, Tso CL, Michel K, deKernion JB, Belldegrun AS 1997 Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res 57:495-499
43. Miyamoto H, Marwah P, Marwah A, Lardy H, Chang C 2003 3 β-Acetoxyandrost-1, 5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. Proc Natl Acad Sci USA 100:4440-4444
44. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G 1998 A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33:447-456
45. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I 2000 Blcalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 164:1579-1582
46. 2000 Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 355:1491-1498
47. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP 1995 Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398
48. Cheng S, Brzostek S, Lee SR, Hollenberg AN, Balk SP 2002 Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol 16:1492-1501
49. Fu M, Wang C, Wang J, Zhang X, Sakamaki T, Yeung YG, Chang C, Hopp T, Fuqua SA, Jaffray E, Hay RT, Palvimo JJ, Janne OA, Pestell RG 2002 Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and transrepression function. Mol Cell Biol 22:3373-3388
50. Karvonen U, Janne OA, Palvimo JJ 2002 Pure antiandrogens disrupt the recruitment of coactivator GRIP1 to colocalize with androgen receptor in nuclei. FEBS Lett 523:43-47
51. Lu J, Matsumoto K, Nishizawa Y, Tanaka A, Hirose T, Sato B 1991 Non-classical androgenic actions of RU38486 in androgen-responsive Shionogi carcinoma 115 cells in serum-free culture. J Steroid Biochem Mol Biol 39:329-335
52. Tovar A, Sanchez-Capelo A, Galindo JD, Cremades A, Penafiel R 1997 Antiandrogenic effect of RU-486 in the mouse kidney. Int J Biochem Cell Biol 29:361-366
53. Mobbs BG, Johnson IE 1991 Suppression of the growth of the androgen-insensitive R3327 HI rat prostatic carcinoma by combined estrogen and antiprogestin treatment. J Steroid Biochem Mol Biol 39:713-722
54. Hackenberg R, Hannig K, Beck S, Schmidt-Rhode P, Scholz A, Schulz KD1996 Androgen-like and anti-androgen-like effects of antiprogestins in human mammary cancer cells. Eur J Cancer 32A:696-701
55. Kokontis J, Ito K, Hiipakka RA, Liao S 1991 Expression and function of normal and LNCaP androgen receptors in androgen-insensitive human prostatic cancer cells. Altered hormone and antihormone specificity in gene transactivation. Receptor 1:271-279
56. Sanchez-Criado JE, Bellido C, Tebar M, Ruiz A, Gonzalez D 1999 The antiprogestin RU486 dissociates LH and FSH secretion In male rats: evidence for direct action at the pituitary level. J Endocrinol 160:197-203
57. Gelmann EP 2002 Molecular biology of the androgen receptor. J Clin Oncol 20:3001-3015
58. Zhang J, Thomas TZ, Kasper S, Matusik RJ 2000 A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 141:4698-4710